Background-Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasingly used to accomplish glycemic targets in patients with type II diabetes mellitus. Because DPP-4 is expressed in inflammatory cells, we hypothesized that its inhibition will exert favorable effects in atherosclerosis.
T ype II diabetes mellitus is a metabolic disorder with multiple derangements in metabolic and immune pathways that predisposes individuals to cardiovascular disease. Although glycemic control is of paramount importance, recent data indicate that broad pleiotropic strategies that target multiple pathways are more likely to succeed in reducing cardiovascular risk in these patients. 1 Emerging evidence suggests an important role for the incretin hormone glucagon-like peptide (GLP-1) in the regulation of postprandial glycemic control and satiety. [2] [3] [4] GLP-1 is inactivated by the exopeptidase dipeptidyl-peptidase 4 (DPP-4), and both inhibitors of DPP-4 (DPP-4i) and DPP-4 -resistant incretin analogs are widely used treatment strategies in type II diabetes mellitus. 5, 6 DPP-4 is expressed in inflammatory cells, including monocyte/macrophages, and was originally described as a T-cell differentiation/activation marker. [7] [8] [9] DPP-4 is well known to recognize and cleave the 2 N-terminal amino acids of DPP-4 -susceptible targets, including GLP-1, cytokines, and chemokines. 9,10 DPP-4 is also a high-affinity ligand for membrane-bound adenosine deaminase and greatly potentiates the activity of adenosine deaminase to inactivate adenosine to inosine. [11] [12] [13] [14] These data suggest that DPP-4 may affect leukocyte migration via the modulation of pericellular purinergic stimuli. 14 -17 In this study, we investigated the effects of DPP-4i in a model of atherosclerosis/insulin resistance.
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Methods
All experiments were performed in accordance with University Laboratory Animal Accreditation Committee guidelines at Ohio State University.
Animal Models
Male low-density lipoprotein receptor-deficient (LDLR Ϫ/Ϫ ) mice (nϭ48; 6 weeks old; Jackson Laboratory, Bar Harbor, ME) were allowed to acclimatize for 4 weeks. The mice were then placed on a high-fat diet (60% energy from fat, Research Diets D12492) or standard laboratory diet (Harlan Teklad, Madison, WI). After 4 weeks on a high-fat diet, baseline metabolic parameters like fasting glucose, insulin, oral glucose tolerance test, weights, and blood pressure were measured. Each group was assigned to treatment with alogliptin (40 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ; Takeda Pharmaceuticals, Oak Grove, IL) or a vehicle for 12 weeks (Figure 1 ). Alogliptin (2-({6-[(3R)-3-aminopiperidinyl-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)yl}methyl)benzonitrile monobenzoate) is a selective DPP-4i, with prior studies demonstrating specific effects on DPP-4 with improvement in glycemic control. 18 The dose for alogliptin was estimated from prior studies in diabetic models. 18 Food intake, water intake, weight, and blood pressure were measured weekly, and the alogliptin dose was adjusted accordingly to maintain a constant daily dose. Systolic blood pressure was measured weekly in conscious mice with a computerized noninvasive tail-cuff manometry system (Visitech IITC model 129 system, Visitech Systems, Apex, NC). Mice were trained for 2 weeks before the experimental procedure.
Systolic blood pressure was recorded for 14 weeks (2 weeks before the start of treatment and 12 weeks of treatment; nϭ7 per group). The first 10 of 20 systolic blood pressure values recorded were disregarded, and the remaining 10 values were collected for analysis. In additional experiments conducted in apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice (nϭ15; 15 weeks of age; Jackson Laboratory, Bar Harbor, ME), animals were allowed to acclimatize for 1 week before experimentation. The mice were placed on a high-fat diet (40% energy from fat; Harlan Diet, Indianapolis, IN) for a duration of 2 weeks, after which they were assigned to treatment with sitagliptin (MK-0431) mixed in water (80 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ; Merck Pharmaceuticals, Whitehouse Station, NJ) or vehicle for an additional 2-weeks. After 2 weeks, mice were euthanized 16 hours after injection of labeled bone marrow-derived macrophages, as described below.
Metabolic Assessment, Plasma DPP-4 Activity, and Cytokine Analysis
A detailed description of the methods used is available in the online-only Data Supplement.
Visceral Adipose Assessment and Quantification of Visceral Fat by Magnetic Resonance Imaging
Flow Cytometry and Fluorescence-Activated Cell Sorter Analysis
Epididymal fat and aorta were isolated from euthanized mice and minced in PBS. Minced tissues were incubated with Collagenase II (Sigma-Aldrich, St. Louis, MO) at 37°C for 30 minutes in a shaker. The digested tissue was centrifuged to obtain stromal vascular fraction pellet, which was further filtered through a cell strainer. Viable leukocytes were obtained from both aorta and epididymal fat with Lympholyte M (Cedarline Laboratories Ltd, Burlington, NC).
Flow Cytometry
Leukocytes were isolated from aorta and visceral fat and resuspended in PBS containing 5% BSA and 0.02% sodium azide (flow buffer). Cells were washed twice and incubated with anti-CD11b, anti-CD11c, anti Ly6C hi , anti-CD11b, and CD206 antibodies for 30 minutes. Cells were subsequently washed with flow buffer, resuspended in 1% formalin, and analyzed with a BD fluorescence-activated cell sorter LSR II flow cytometer (Becton Dickinson, San Jose, CA) and BD fluorescence-activated cell sorter Diva software (Becton Dickinson).
Quantification of Atherosclerosis and Functional Vascular Assessment
Detailed methods are provided in the online-only Data Supplement. The heart and ascending aorta were dissected and fixed with paraformaldehyde for 72 hours. The aortic root and adjacent heart were embedded in paraffin, and 5-m-thick sections were obtained from the annulus extending through the sinus region. Sections were stained with hematoxylin and eosin, Masson trichrome, and Oil Red O. Atherosclerotic quantification was performed as described previously. 19 Immunofluorescent staining for quantification of F4/80-positive cells was performed as previously described. 20, 21 Thoracic aortic ring segments were suspended in myograph chambers and evaluated as previously described. 
In-Vivo Migration Assays in Atherosclerosis
A detailed methods description is available in the online-only Data Supplement.
In Vitro Monocyte Migration Assays
Human monocytes (THP-1) and mouse bone marrow-derived monocytes were used to study migration patterns with DPP-4i agents (50 mol/L alogliptin and 100 mol/L sitagliptin) as described in the online-only Data Supplement. We based our in vitro doses on human pharmacokinetic studies in which levels such as those used may be attained after oral dosing of the drug. [22] [23] [24] 
Rac-1 Activity
Total Rac1 and activated Rac1 (GTP bound) were quantified from monocytes with Western blot analysis. Half of the cell lysates were subjected to a commercially available Rac1/Cdc42 activation assay kit (Upstate Biotechnology, Temecula, CA), which precipitated activated Rac-1. All samples were boiled in Laemmli buffer (62.5 mmol/L Tris-HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue) and then subjected to SDS-PAGE (12% acrylamide). Rac-1 was quantified with Rac-1 antibody (Millipore, Temecula, CA).
Filamentous Actin Staining
Statistical Analysis
Data are expressed as meanϮSD unless otherwise indicated. Comparison of continuous variables was conducted with 2-way ANOVA to account for the effect from both treatment and diet. If significant results were identified in 2-way ANOVA, post hoc Bonferroni correction was applied for multiple comparison adjustment. In all tests, PϽ0.05 was considered significant. For responses measured repeatedly at different time points, the test was applied to the measurements at the last time point to determine the overall effect. Statistical analysis was performed with Graph Pad Prism (version 4). mice gained significantly more weight compared with normal chow diet-fed mice at the end of 12 weeks. Table 1 depicts weights, food intake, water intake, and lipid and metabolic parameters at the end of the 12-week period. DPP-4i did not change weekly weight or food consumption in either diet group. After 12 weeks, the HD group exhibited significantly lower levels of fasting and post-glucose-load levels compared with the HV group ( Figure 1B and Table 1 ). Figure 1C demonstrates a marked improvement in insulin resistance (homeostasis model assessment-insulin resistance) and ␤-cell function (homeostasis model assessment-␤) in HD mice compared with the HV group. Systolic blood pressure values increased over time in response to the high-fat diet, with lowering of systolic blood pressure in the HD group, an effect that was apparent as early as 4 weeks after treatment ( Figure  1D ). Administration of DPP-4i reduced DPP-4 activity in the plasma, as expected, in both ND and HD mice. High-fat diet increased DPP-4 activity in the plasma by 2.9-fold in HV compared with the NV group ( Figure 1E ). Plasma GLP-1 levels were significantly elevated in response to DPP-4i in the ND and HD groups. Figure II in the online-only Data Supplement depicts plasma cytokine and chemokine measures. The HV group demonstrated an increase in plasma tumor necrosis factor-␣ (TNF␣) compared with NV, whereas DPP-4i resulted in a reduction of TNF␣. Interleukin-6 levels were reduced in the HD group compared with the HV group.
Results
Long-Term DPP-4 Inhibition Improves Metabolic Indexes and Blood Pressure
DPP-4 Inhibition Results in Visceral Adipose Remodeling
Figure 2A depicts quantification of visceral and subcutaneous adipose tissue in mice from various groups. HV mice had a 2.8-fold increase in abdominal adipose deposition that was attenuated in the DPP-4i group compared with vehicle. These changes were accompanied by smaller adipocyte size/area in the drug group compared with vehicle ( Figure 2B ). Figure 2C illustrates a reduction in plasma leptin and resistin levels in the DPP-4i group compared with the vehicle-treated HV animals. Plasma adiponectin levels were reduced in response to high-fat diet with a reversal of this decrease with DPP-4i.
Long-Term DPP-4i Reduces Recruitment of Inflammatory Monocyte/Macrophages
To assess the effects of DPP-4i on adipose inflammation, we analyzed adipose tissue macrophage content in the stromal vascular fraction and analyzed gene expression for classic markers of M1 and M2 differentiation. Immunohistochemical analysis of visceral adipose samples demonstrated a reduction in F4/80 ϩ macrophages with DPP-4i ( Figure 3A ). Figure 3B depicts flow cytometric studies on the stromal vascular fraction extracted from the adipose tissue. As is evident in Figure 3B , there was a 315% increase in CD11b ϩ Ly6C hi cells with high-fat diet compared with normal chow diet when adjusted for weight of adipose tissue. DPP-4i reduced CD11b ϩ Ly6C hi cells by 100%. These results sug- gest that DPP-4i treatment may modulate recruitment of proinflammatory monocytes. 25, 26 Prior work by Lumeng and colleagues 27 has demonstrated an important role for proinflammatory CD11b ϩ CD11c ϩ adipose tissue macrophages in the pathogenesis of insulin resistance. DPP-4i treatment decreased double-positive cells by 200% compared with HV mice.
We then analyzed the expression of genes that typify M1 (classically activated) and M2 (alternately activated) macrophage activation states using the stromal vascular fraction of experimental mice. Recent studies seem to indicate excessive activation of toll-like receptor-4 pathways by endogenous toll-like receptor-4 ligands such as free fatty acids in insulin resistance, with an effect of DPP-4i on toll-like receptor-4 signaling. 28, 29 Figure 3C depicts an increase in the expression of M2 markers (CD163 and Ym-1) with DPP-4i treatment without changes in other M1 markers, including TNF␣ and interleukin-6. Taken together, these results suggest DPP-4i reduces proinflammatory gene expression and mediates reversion to an alternatively activated macrophage phenotype. Figure 4A depicts the results of quantitative evaluation of plaque burden at the level of the aortic sinuses. The HV group was associated with a 6-fold increase in plaque burden compared with the NV group, whereas DPP-4i reduced plaque by 3.5-fold compared with HV. This reduction was associated with a parallel decline in plaque macrophages ( Figure 4B ) and plaque collagen ( Figure 4C ). Figure 4D depicts flow cytometric evaluation of CD11b ϩ and CD206 ϩ macrophages within plaque. Overall CD11b ϩ cells constituted 30% of the overall mononuclear population in the aorta of the NV group and 50% of the cell population in the HD group. The HV group revealed a 3-fold increase in the number of CD11b ϩ macrophages and a 5-fold increase in CD11b ϩ CD206 ϩ macrophages. There was a reduction in CD11b ϩ and CD11b ϩ CD206 ϩ cells in the HD groups compared with HV. Figure III in the online-only Data Supplement illustrates the results of myograph experiments performed on thoracic aortic segments. DPP-4i resulted in an improvement in acetylcholine-dependent relaxation of aortic segments and an attenuation of vasoconstriction in response to phenylephrine. 
Long-Term DPP-4 Inhibition Results in Reduced Plaque Burden and Inflammation
Effects of DPP-4 Inhibition on Activation and Migration of Immune Cells
To evaluate the effects of DPP-4i on monocyte gene expression, we analyzed expression of candidate inflammatory pathways. CD11b ϩ cells were isolated from bone marrow by fluorescence-activated cell sorter from the various experimental groups. Treatment with a DPP-4i resulted in reduction in TNF␣ (PϽ0.05); a decreasing trend, although not statistically significant, was also seen in interleukin-6 (Pϭ0.06) and monocyte chemoattractant protein-1 (Pϭ0.06) mRNA levels, suggesting an effect on the inflammatory potential of these cells ( Figure 5A ). CD11b monocytes from HV animals highly expressed DPP-4 compared with normal chow diet-fed animals. GLP-1R also was expressed by these cells with no difference between experimental groups (data not shown).
In vitro transmigration assays on cultured human and murine bone marrow-derived monocytes were performed to explore the effects of DPP-4i on the migratory properties of these cells. Migration assays were performed in response to CCL-2 and CCL-5 gradients in the presence and absence of nanomolar TNF␣ as described previously. 30,31 DPP-4 is known to associate with adenosine deaminase and may thereby modulate pericellular adenosine concentrations. 11, 14 Experiments were performed in the presence and absence of adenosine receptor antagonists (Ad2RA) and an inhibitor of Rac activation. Figure 5B shows responses in cultured murine bone marrow-derived monocytes; Figure IVA potentiated monocyte migration to a CCL-2 gradient. Inhibition of DPP-4 with both alogliptin and sitagliptin reduced monocyte migration in response to CCL-2. Preincubation of monocytes with adenosine receptor 2A antagonist (ZM 241385) resulted in the neutralization of the antichemotactic effect of alogliptin ( Figure 5C ). Preincubation with Exendin(9 -39) (an inactive nonmammalian GLP-1 fragment that antagonizes GLP-1) 32 had no effect on monocyte migration in response to the stimuli. Pretreatment with the Rac1 inhibitor NSC 23766 resulted in a decreased migration to TNF␣ stimulation, indicating that Rac1 is involved in chemotaxis. Parallel Rac-GTP pull-down assays were performed to detect the effects of alogliptin and sitagliptin pretreatment on the activation of Rac and to evaluate the role of adenosine 2A receptor in modulating the effects of these drugs ( Figure 5C and Figure V in the online-only Data Supplement). Pretreatment with the DPP-4i alogliptin (50 mol/L) and sitagliptin (100 mol/L) reduced the level of active Rac1 after stimulation by TNF␣ and monocyte chemoattractant protein-1. This effect was blunted by adenosine receptor 2A antagonist (ZM 241385) after pretreatment with alogliptin ( Figure 5C ) but not by sitagliptin ( Figure V in the online-only Data Supplement). The reasons for the difference between the 2 compounds on adenosine receptor signaling are currently unclear but may relate to a combination of chemical structure differences, dose, or both. Figure 5D shows actin polymerization induced by TNF␣ that was inhibited with the pretreatment of cells with alogliptin. Additionally, antipolymerization effects on actin filaments by alogliptin were reversed by adenosine receptor 2A antagonist (ZM 241385). These experiments suggest that DPP-4i results in decreased chemotaxis of immune cells via Rac1-dependent pathways.
To further evaluate the significance of the in vitro effects of DPP-4-i on migration and to validate the effects in an alternate model of atherosclerosis, we conducted experiments on ApoE Ϫ/Ϫ mice on high-fat diet that were treated with sitagliptin or vehicle for a 2-week period. Two weeks of treatment with sitagliptin reduced DPP-4 activity by Ͼ75% (data not shown). We used an in vivo model of chemotactic migration to plaque using an inflammatory stimulus (TNF␣ injected intraperitoneally). The injection of labeled cells (carboxyfluorescein succinimidyl ester) has previously been shown to migrate to the plaque, with the extent of migration representing an index of chemotactic ability. 33 We first confirmed that these cells indeed express DPP-4. Figure 6A depicts results of flow cytometry that reveal that Ͼ90% of these cells express DPP-4. Figure 6B represents flow cytometric plots for carboxyfluorescein succinimidyl ester-labeled bone marrow-derived monocytes isolated from the aorta of ApoE Ϫ/Ϫ mice. We then evaluated the effects of exogenously injected DPP-4. The administration of DPP-4 in these experiments revealed a marked promigratory effect of this protein consistent with prior experiments in lymphocytes. 34 Pretreatment with DPP-4i prevented the migration of cells to the aorta ( Figure 6C ). Figure V in the online-only Data Supplement depicts results of migration to the peritoneal cavity under identical conditions performed in a subset of mice that demonstrated a potent effect of DPP-4i in preventing migration into the peritoneal cavity in response to DPP-4 and TNF␣.
Discussion
In this article, we demonstrate an important effect of DPP-4i in reducing atherosclerosis. Reduction in atherosclerosis was accompanied by favorable alterations in metabolic and inflammatory parameters. Notably, these changes occurred without differences in weight loss in the animals, consistent with weight neutrality of DPP-4i noted in clinical studies. 5, 35 The mechanisms appear to be related to inhibition of DPP-4 -mediated alterations in monocyte chemotaxis, occurring via changes in Rac-dependent actin-cytoskeletal interactions.
DPP-4 (CD26) is a membrane-bound exopeptidase highly expressed in lipid rafts of inflammatory cells such as lymphocytes and monocytes. 8, 9 The enzyme catalyzes the release of N-terminal dipeptides from oligopeptides/polypeptides with proline/hydroxyproline in the penultimate position. 10 DPP-4 is present on the cell surface but is also secreted. Furthermore, the cysteine-rich region of DPP-4 contains fibronectin and collagen-binding sites through which it may associate with extracellular matrix. DPP-4 cleaves and inactivates multiple peptide substrates, including the incretin hormones GLP-1 and glucose-dependent insulinotropic poly- peptide, thereby influencing glycemic control. 36, 37 However, the nonglycemic role of DPP-4 and, in particular, its role in the regulation of inflammation may allow its participation in the pathogenesis of chronic inflammatory disease.
DPP-4i resulted in improvements in insulin resistance, postprandial glucose, inflammatory cytokines, and adipokines in the plasma. A reduction in inflammatory monocytes (CD11b ϩ Ly6C hi ) was discernible in the adipose, along with improvement in adipocyte area and a reduction in visceral adipose content. There was a reduction in monocytes in the plaque-expressing proinflammatory genes. These changes suggest potent effects of DPP-4i on inflammation, medi- ated potentially via its effects on monocyte recruitment to tissue niches and alteration of monocyte activation, as evidenced by an increase in markers of alternate macrophage activation such as CD163 and Ym-1 in adipose tissue macrophages.
How might DPP-4i modulate monocyte recruitment into visceral adipose tissue? DPP-4 exopeptidase activity has been shown to play a role in the processing of chemokines and may modulate the chemotactic behavior of cells. 28, 38 The enzyme has been described as an adenosine deaminase-binding protein. [11] [12] [13] [14] Membrane-bound DPP-4 is a high-affinity receptor for adenosine deaminase. Binding to adenosine deaminase does not require the catalytic domain of DPP-4 and does not induce enzymatic or conformational changes. This pair of enzymes is thought to be involved in immunoregulatory mechanisms through the control of pericellular adenosine concentrations. 11, 12 Recent studies indicate that purinergic stimuli are critical in mediating movement of inflammatory cells toward a chemokine stimulus. 15, 39 Activation of adenosine A2B receptors has been shown to dampen chemotaxis and chemokinesis. 40 Results from migration assays seem to suggest a role for DPP-4 in regulating chemotaxis in response to chemokines (CCL-2 and CCL-5) and inflammatory mediators (TNF␣) that is dependent on Rac signaling. Indeed, monocytes upregulated DPP-4 expression both in vivo and in response to differentiation in vitro. High-fat feeding markedly increased DPP-4 activity and expression. With these results taken together with the promigratory properties of this molecule, it is reasonable to hypothesize that the effects of DPP-4i may be modulated through effects on this pathway.
Active, GTP-bound Rac1 plays an important role in regulating cell migration through the modulation of actin-rich lamellipodial protrusions, critical components for generating the driving force of cell movement. In several systems, inhibition of Rac results in cessation of cell movement. 31, 40, 41 In our study, preincubation of monocytes with a Rac-1 antagonist resulted in the neutralization of the antichemotactic effect of alogliptin and sitagliptin, whereas Exendin(9 -39) (inactive GLP-1 fragment) did not have such an effect, suggesting that the effects on in vitro migration were GLP-1 receptor independent. DPP-4i reduced atherosclerosis and improved vascular function. Both GLP-1 (via DPP-4i) and non-GLP-1 mechanisms may activate PI3K-Akt-endothelial nitric oxide synthase, may improve nitric oxide release, and may confer additional benefits. 42, 43 Consistent with this, there was a 20-mm Hg reduction in blood pressure at the end of 10 weeks, which was evident as early as 4 weeks after treatment. It is conceivable that the improvement in vascular function and atherosclerosis may have also resulted from the antiinflammatory effects of DPP-4i. Our experiments suggest a prominent effect on inflammatory migration of monocytes as early as 2 weeks after treatment, a time point at which no effects on blood pressure were seen (Figure 1 ). This finding suggests that the antiinflammatory effects may well precede blood pressure effects and may mediate improvements in endothelial function and atherosclerosis. Nevertheless, it may be difficult to completely exclude the incretin effects of DPP-4i as a potential mediator of beneficial effects in vivo.
The incretin axis (GLP-1 receptors, glucose-dependent insulinotropic polypeptide receptors and DPP-4) is widely expressed in the cardiovascular system, with prior work suggesting that ligation of the GLP-1 receptor by GLP-1 in both cardiomyocytes and endothelial cells resulting in upregulation of cell survival pathways and endothelial function. 3, [42] [43] [44] [45] [46] Thus, an increase in GLP-1 as a consequence of DPP-4i may represent an important additional mechanism of benefit. 43, [47] [48] [49] Additional lines of evidence suggest GLP-1R-independent vascular effects of GLP-1 and truncated peptides of GLP-1 such as Exendin . 50 The vasodilatory effects of both GLP-1 and GLP-1(9-36) correlate with an increase in cGMP release and are typically attenuated by preincubation of vessels with nitric oxide synthase inhibitors, suggesting that at least part of their vasodilatory mechanism is nitric oxide/cGMP dependent.
Our results suggest broad pleiotropic effects of DPP-4i and suggest a potential role for these agents in retarding atherosclerosis and related complications in type II diabetes mellitus.
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